BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31001805)

  • 1. High-resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma.
    Sepulveda JL; Komissarova EV; Kongkarnka S; Friedman RA; Davison JM; Levy B; Bryk D; Jobanputra V; Del Portillo A; Falk GW; Sonett JR; Lightdale CJ; Abrams JA; Wang TC; Sepulveda AR
    Int J Cancer; 2019 Nov; 145(10):2754-2766. PubMed ID: 31001805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2A-p16 Deletion and Activated KRAS
    Sun J; Sepulveda JL; Komissarova EV; Hills C; Seckar TD; LeFevre NM; Simonyan H; Young C; Su G; Del Portillo A; Wang TC; Sepulveda AR
    Cell Mol Gastroenterol Hepatol; 2024; 17(5):769-784. PubMed ID: 38296052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.
    Stachler MD; Camarda ND; Deitrick C; Kim A; Agoston AT; Odze RD; Hornick JL; Nag A; Thorner AR; Ducar M; Noffsinger A; Lash RH; Redston M; Carter SL; Davison JM; Bass AJ
    Gastroenterology; 2018 Jul; 155(1):156-167. PubMed ID: 29608884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
    Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
    Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
    Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
    Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
    Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
    J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus.
    Li X; Galipeau PC; Paulson TG; Sanchez CA; Arnaudo J; Liu K; Sather CL; Kostadinov RL; Odze RD; Kuhner MK; Maley CC; Self SG; Vaughan TL; Blount PL; Reid BJ
    Cancer Prev Res (Phila); 2014 Jan; 7(1):114-27. PubMed ID: 24253313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
    Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
    Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole Genome Methylation Analysis of Nondysplastic Barrett Esophagus that Progresses to Invasive Cancer.
    Dilworth MP; Nieto T; Stockton JD; Whalley CM; Tee L; James JD; Noble F; Underwood TJ; Hallissey MT; Hejmadi R; Trudgill N; Tucker O; Beggs AD
    Ann Surg; 2019 Mar; 269(3):479-485. PubMed ID: 29384778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus].
    Osminin SV; Vetshev FP; Rudenko VV; Zaletaev DV; Khorobrykh TV; Nemtsova MV
    Klin Lab Diagn; 2016 Oct; 61(10):681-5. PubMed ID: 30615323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas.
    Michael D; Beer DG; Wilke CW; Miller DE; Glover TW
    Oncogene; 1997 Oct; 15(14):1653-9. PubMed ID: 9349498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Array-based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma.
    Albrecht B; Hausmann M; Zitzelsberger H; Stein H; Siewert JR; Hopt U; Langer R; Höfler H; Werner M; Walch A
    J Pathol; 2004 Jul; 203(3):780-8. PubMed ID: 15221937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.
    Buas MF; Levine DM; Makar KW; Utsugi H; Onstad L; Li X; Galipeau PC; Shaheen NJ; Hardie LJ; Romero Y; Bernstein L; Gammon MD; Casson AG; Bird NC; Risch HA; Ye W; Liu G; Corley DA; Blount PL; Fitzgerald RC; Whiteman DC; Wu AH; Reid BJ; Vaughan TL
    Carcinogenesis; 2014 Dec; 35(12):2740-7. PubMed ID: 25280564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
    Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
    Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
    J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
    Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.